Zentalis Pharmaceuticals
ZNTL
ZNTL
128 hedge funds and large institutions have $2.03B invested in Zentalis Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 48 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
43% less capital invested
Capital invested by funds: $3.58B → $2.03B (-$1.55B)
Holders
128
Holding in Top 10
4
Calls
$6.79M
Puts
$1.38M
Top Buyers
| 1 | +$33.9M | |
| 2 | +$21.3M | |
| 3 | +$10.7M | |
| 4 |
Morgan Stanley
New York
|
+$6.81M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.41M |
Top Sellers
| 1 | -$16M | |
| 2 | -$15.1M | |
| 3 | -$9.33M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.52M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.61M |